Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$0.17 - $0.38 $167,398 - $374,185
-984,698 Reduced 73.81%
349,471 $62,000
Q3 2023

Nov 14, 2023

BUY
$0.31 - $1.78 $413,592 - $2.37 Million
1,334,169 New
1,334,169 $440,000

About Aptevo Therapeutics Inc.


  • Ticker APVO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 5,090,640
  • Market Cap $24.5M
  • Description
  • Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelo...
More about APVO
Track This Portfolio

Track Sabby Management, LLC Portfolio

Follow Sabby Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sabby Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sabby Management, LLC with notifications on news.